Search Page

1

Cite

Share

What next after GDP-based cost-effectiveness thresholds?

Chi YL, Blecher M, Chalkidou K, Culyer A, Claxton K, Edoka I, Glassman A, Kreif N, Jones I, Mirelman AJ, Nadjib M, Morton A, Norheim OF, Ochalek J, Prinja S, Ruiz F, Teerawattananon Y, Vassall A, Winch A. Chi YL, et al. Among authors: ochalek j. Gates Open Res. 2020 Nov 30;4:176. doi: 10.12688/gatesopenres.13201.1. eCollection 2020. Gates Open Res. 2020. PMID: 33575544 Free PMC article.

Cite

Share

2

Cite

Share

Cost-Effectiveness Thresholds: the Past, the Present and the Future.

Thokala P, Ochalek J, Leech AA, Tong T. Thokala P, et al. Among authors: ochalek j. Pharmacoeconomics. 2018 May;36(5):509-522. doi: 10.1007/s40273-017-0606-1. Pharmacoeconomics. 2018. PMID: 29427072 Free article. Review.

Cite

Share

3

Cite

Share

Valuing health outcomes: developing better defaults based on health opportunity costs.

Ochalek J, Claxton K, Lomas J, Thompson KM. Ochalek J, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):729-736. doi: 10.1080/14737167.2020.1812387. Epub 2020 Sep 20. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 32954900 Free article.

Cite

Share

4

Cite

Share

Accounting for Timing when Assessing Health-Related Policies.

Claxton K, Asaria M, Chansa C, Jamison J, Lomas J, Ochalek J, Paulden M. Claxton K, et al. Among authors: ochalek j. J Benefit Cost Anal. 2019 Jan 26;10(Suppl 1):73-105. doi: 10.1017/bca.2018.29. J Benefit Cost Anal. 2019. PMID: 33282628 Free PMC article.

Cite

Share

5

Cite

Share

Supporting the development of a health benefits package in Malawi.

Ochalek J, Revill P, Manthalu G, McGuire F, Nkhoma D, Rollinger A, Sculpher M, Claxton K. Ochalek J, et al. BMJ Glob Health. 2018 Apr 9;3(2):e000607. doi: 10.1136/bmjgh-2017-000607. eCollection 2018. BMJ Glob Health. 2018. PMID: 29662689 Free PMC article.

Cite

Share

6

Cite

Share

Concomitant health benefits package design and research prioritisation: development of a new approach and an application to Malawi.

Schmitt L, Ochalek J, Claxton K, Revill P, Nkhoma D, Woods B. Schmitt L, et al. Among authors: ochalek j. BMJ Glob Health. 2021 Dec;6(12):e007047. doi: 10.1136/bmjgh-2021-007047. BMJ Glob Health. 2021. PMID: 34903565 Free PMC article.

Cite

Share

7

Cite

Share

Squaring the cube: Towards an operational model of optimal universal health coverage.

Ochalek J, Manthalu G, Smith PC. Ochalek J, et al. J Health Econ. 2020 Mar;70:102282. doi: 10.1016/j.jhealeco.2019.102282. Epub 2020 Jan 16. J Health Econ. 2020. PMID: 31955865 Free PMC article.

Cite

Share

8

Cite

Share

Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries.

Ochalek J, Abbas K, Claxton K, Jit M, Lomas J. Ochalek J, et al. BMJ Glob Health. 2020 Oct;5(10):e003006. doi: 10.1136/bmjgh-2020-003006. BMJ Glob Health. 2020. PMID: 33082132 Free PMC article.

Cite

Share

9

Cite

Share

Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach.

Ochalek J, Wang H, Gu Y, Lomas J, Cutler H, Jin C. Ochalek J, et al. Pharmacoeconomics. 2020 Dec;38(12):1319-1331. doi: 10.1007/s40273-020-00954-y. Pharmacoeconomics. 2020. PMID: 32856280

Cite

Share

10

Cite

Share

Causal effects of HIV on employment status in low-income settings.

Ochalek J, Revill P, van den Berg B. Ochalek J, et al. Econ Hum Biol. 2017 Nov;27(Pt A):248-260. doi: 10.1016/j.ehb.2017.09.001. Epub 2017 Sep 8. Econ Hum Biol. 2017. PMID: 28930699 Free article.

Cite

Share